10X Genomics Hits New 52-Week High at $43.21, Up 92.65% Year-Over-Year

10X Genomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 43.21 on July 10, 2026. This achievement marks a remarkable increase from its 52-week low of USD 11.16, showcasing a substantial growth trajectory over the past year. The company's performance over the last year has been impressive, with a gain of 92.65%, significantly outpacing the S&P 500's performance of 20.62%. Despite being a loss-making entity, 10X Genomics has managed to carve out a notable position in its industry, reflected in its market capitalization of USD 2,489 million. Key financial metrics indicate a price-to-book ratio of 3.13, while the company operates with a debt-to-equity ratio of -0.64 and a return on equity of -10.80%. With no dividend yield reported, the focus remains on the company's growth and market positioning within the competitive landscape of biotechnology.